The shares of this pharma company gained up to 8 percent after the company’s net profit and revenue increased by 222 percent and 33 percent YoY, respectively in Q1FY25.
With a market capitalization of Rs 7,446.07 crore, the shares of Orchid Pharma Ltd were trading at Rs 1,468.10 per share, decreasing around 0.61 percent as compared to the previous closing price of Rs 1477.90 apiece.
Reason for Rise:-
The shares of Orchid Pharma have seen such a bullish movement after revenue magnified 12 percent on a Quarter basis from Rs 217 crore in Q4FY24 to Rs 244 crore Q1FY25, if we look into the on Year on Year basis revenue magnified significantly by 33 percent from Rs 183 crore Q1FY24 to Rs 244 crore Q1FY25.
Orchid Pharma Ltd’s net profit plummeted by 12 percent on a quarter-on-quarter basis from Rs. 33 crores in Q4FY24 to Rs 29 in Q1FY25. Further, on a year-on-year basis also net profit magnified drastically by 222 percent from Rs 9 crores in Q1FY24 to Rs. 29 crores in Q1FY25.
Remarkable return & recent approval:-
The shares have been given a return of 34 percent in the period of six months and a multi-bagger return of 164 percent in 1 year. If an individual invested Rs 1 lakh a year ago it will be worth it now Rs 2.65 lakh.
Orchid Pharma’s innovative medicine Enmetazobactam was authorized in both the United States and Europe in Q4 FY23-24 and will be marketed soon, a significant success for India because it is the first drug created in India to attain this milestone.
Ratio analysis:-
Examining the company’s crucial ratio, return on equity inclined from 6.72 percent in FY22-23 to 7.88 percent in FY23-24, while during the same time frame return on capital employed also inclined from 5.65 percent to 8.37 percent. In contrast, the net profit margin (NPM) stands at 11.60 percent in fiscal year 23-24.
Orchid Pharma Limited manufactures integrated active medicinal components. It operates in the pharmaceutical sector. It has several therapeutic applications, including anti-infectives, anti-inflammatory, CNS, CVS, nutraceuticals, and oral/sterile products.
Written by:- Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
